PL1689404T3 - Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka - Google Patents
Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia rakaInfo
- Publication number
- PL1689404T3 PL1689404T3 PL04798717T PL04798717T PL1689404T3 PL 1689404 T3 PL1689404 T3 PL 1689404T3 PL 04798717 T PL04798717 T PL 04798717T PL 04798717 T PL04798717 T PL 04798717T PL 1689404 T3 PL1689404 T3 PL 1689404T3
- Authority
- PL
- Poland
- Prior art keywords
- combination
- cancer
- drugs
- treatment
- fluorouracil
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title 1
- 229960002949 fluorouracil Drugs 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 abstract 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 abstract 3
- 229960004117 capecitabine Drugs 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51969003P | 2003-11-13 | 2003-11-13 | |
| PCT/GB2004/050026 WO2005049031A1 (en) | 2003-11-13 | 2004-11-15 | Combination |
| EP04798717A EP1689404B9 (en) | 2003-11-13 | 2004-11-15 | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1689404T3 true PL1689404T3 (pl) | 2009-02-27 |
Family
ID=34619369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04798717T PL1689404T3 (pl) | 2003-11-13 | 2004-11-15 | Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7622458B2 (pl) |
| EP (1) | EP1689404B9 (pl) |
| JP (1) | JP2007511499A (pl) |
| AT (1) | ATE406897T1 (pl) |
| CA (1) | CA2544320A1 (pl) |
| CY (1) | CY1108629T1 (pl) |
| DE (1) | DE602004016376D1 (pl) |
| DK (1) | DK1689404T3 (pl) |
| ES (1) | ES2314470T3 (pl) |
| HR (1) | HRP20080598T3 (pl) |
| PL (1) | PL1689404T3 (pl) |
| PT (1) | PT1689404E (pl) |
| RS (1) | RS50692B (pl) |
| SI (1) | SI1689404T1 (pl) |
| WO (1) | WO2005049031A1 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| WO2002036135A2 (en) * | 2000-11-06 | 2002-05-10 | Pharma Mar, S.A. | Compositions for antitumour treatment containing ecteinascidin 743 |
| GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
| JP2007511499A (ja) | 2003-11-13 | 2007-05-10 | ファーマ・マール・エス・アー・ウー | コンビネーション |
| JP2007511509A (ja) * | 2003-11-14 | 2007-05-10 | ファルマ・マール・ソシエダード・アノニマ | Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法 |
| RS50822B (sr) * | 2004-10-26 | 2010-08-31 | Pharma Mar S.A., Sociedad Unipersonal | Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743 |
| KR101188691B1 (ko) * | 2004-10-29 | 2012-10-09 | 파르마 마르 에스.에이. | 엑티나시딘 및 디사카라이드를 포함하는 제제 |
| ATE546148T1 (de) * | 2005-07-21 | 2012-03-15 | Nuvo Res Ag | Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| RU2325914C2 (ru) * | 2006-06-15 | 2008-06-10 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ лечения операбельного рака молочной железы |
| WO2009050303A1 (en) * | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Prognostic molecular markers for et-743 treatment |
| EP2786755A3 (en) | 2010-11-12 | 2014-10-29 | Pharma Mar S.A. | Combination therapy with an antitumor alkaloid |
| LT3615544T (lt) | 2017-04-27 | 2023-05-10 | Pharma Mar S.A. | Priešnavikiniai junginiai |
| CA3090748A1 (en) * | 2018-02-12 | 2019-08-15 | Array Biopharma Inc. | Methods and combination therapy to treat biliary tract cancer |
| CA3158733A1 (en) | 2019-11-21 | 2021-05-27 | Pilar Calvo | Methods of treating small cell lung cancer with lurbinectedin formulations |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| US5256663A (en) | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| US5149804A (en) | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
| DE3635711A1 (de) | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
| FR2697752B1 (fr) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| AU671491B2 (en) * | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US20040059112A1 (en) | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
| GB9508195D0 (en) | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
| US5721362A (en) | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
| US5985876A (en) | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| BR9909488B1 (pt) | 1998-04-06 | 2011-02-08 | ecteinascidinas semi-sintéticas e composição farmacêutica. | |
| IL139607A0 (en) | 1998-05-11 | 2002-02-10 | Pharma Mar Sa | Metabolites of ecteinascidin 743 |
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| MY130271A (en) | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
| DE60124387T2 (de) * | 2000-02-28 | 2007-10-11 | Pfizer Enterprises Sarl. | Synergistische pharmazeutische Zusammensetzungen zur Behandlung von kolorektalem Krebs |
| KR100886496B1 (ko) | 2000-04-12 | 2009-03-05 | 파르마 마르, 에스.에이. | 항종양성 엑티나시딘 유도체 |
| US20020137663A1 (en) | 2000-08-11 | 2002-09-26 | Forman Barry M. | The anti-neoplastic agent ET-743 inhibits trans activation by SXR |
| WO2002036135A2 (en) * | 2000-11-06 | 2002-05-10 | Pharma Mar, S.A. | Compositions for antitumour treatment containing ecteinascidin 743 |
| WO2002064843A1 (en) | 2001-02-09 | 2002-08-22 | The Regents Of The University Of California | Ecteinascidin family compounds: compositions and methods |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| PL368458A1 (pl) | 2001-10-19 | 2005-03-21 | Pharmamar S.A. | Zastosowanie związku przeciwrakowego przy ulepszonym harmonogramie dawkowania, do leczenia raka |
| US20040019027A1 (en) | 2002-04-12 | 2004-01-29 | Barry Forman | Method of treating cerebrotendinous xanthomatosis |
| GB0312407D0 (en) | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
| GB0324201D0 (en) | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
| JP2007511499A (ja) | 2003-11-13 | 2007-05-10 | ファーマ・マール・エス・アー・ウー | コンビネーション |
| GB0326486D0 (en) | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| JP2007511509A (ja) | 2003-11-14 | 2007-05-10 | ファルマ・マール・ソシエダード・アノニマ | Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法 |
| WO2006035244A2 (en) | 2004-09-29 | 2006-04-06 | Pharma Mar S.A., Sociedad Unipersonal | Ecteinascidin compounds as anti -inflammatory agents |
| RS50822B (sr) | 2004-10-26 | 2010-08-31 | Pharma Mar S.A., Sociedad Unipersonal | Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743 |
| KR101188691B1 (ko) | 2004-10-29 | 2012-10-09 | 파르마 마르 에스.에이. | 엑티나시딘 및 디사카라이드를 포함하는 제제 |
-
2004
- 2004-11-15 JP JP2006538970A patent/JP2007511499A/ja active Pending
- 2004-11-15 WO PCT/GB2004/050026 patent/WO2005049031A1/en not_active Ceased
- 2004-11-15 SI SI200430928T patent/SI1689404T1/sl unknown
- 2004-11-15 CA CA002544320A patent/CA2544320A1/en not_active Abandoned
- 2004-11-15 AT AT04798717T patent/ATE406897T1/de active
- 2004-11-15 EP EP04798717A patent/EP1689404B9/en not_active Expired - Lifetime
- 2004-11-15 RS RSP-2008/0567A patent/RS50692B/sr unknown
- 2004-11-15 HR HR20080598T patent/HRP20080598T3/xx unknown
- 2004-11-15 US US10/579,160 patent/US7622458B2/en not_active Expired - Fee Related
- 2004-11-15 ES ES04798717T patent/ES2314470T3/es not_active Expired - Lifetime
- 2004-11-15 PL PL04798717T patent/PL1689404T3/pl unknown
- 2004-11-15 DK DK04798717T patent/DK1689404T3/da active
- 2004-11-15 DE DE602004016376T patent/DE602004016376D1/de not_active Expired - Lifetime
- 2004-11-15 PT PT04798717T patent/PT1689404E/pt unknown
-
2008
- 2008-12-02 CY CY20081101393T patent/CY1108629T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2544320A1 (en) | 2005-06-02 |
| RS50692B (sr) | 2010-06-30 |
| PT1689404E (pt) | 2008-12-15 |
| DK1689404T3 (da) | 2009-01-26 |
| SI1689404T1 (sl) | 2009-02-28 |
| WO2005049031A1 (en) | 2005-06-02 |
| US7622458B2 (en) | 2009-11-24 |
| EP1689404B1 (en) | 2008-09-03 |
| HRP20080598T3 (en) | 2009-01-31 |
| JP2007511499A (ja) | 2007-05-10 |
| EP1689404A1 (en) | 2006-08-16 |
| ATE406897T1 (de) | 2008-09-15 |
| US20070190164A1 (en) | 2007-08-16 |
| CY1108629T1 (el) | 2014-04-09 |
| DE602004016376D1 (de) | 2008-10-16 |
| ES2314470T3 (es) | 2009-03-16 |
| EP1689404B9 (en) | 2009-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108629T1 (el) | Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου | |
| IL273765A (en) | Combinations and forms of administration of therapeutic agents and combined treatment | |
| WO2004062604A3 (en) | Treatment of cancer with 2-deoxyglucose | |
| NZ544472A (en) | Compounds and therapeutical use thereof | |
| ZA200107920B (en) | Apomorphine and sildenafil composition. | |
| IL155781A0 (en) | Effective antitumor treatments | |
| SI1551409T1 (sl) | Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka | |
| MY164077A (en) | Compositions and uses of et743 for treating cancer | |
| NO20072543L (no) | Anti-cancer-behandling | |
| BR0313117A (pt) | Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
| WO2000057867A3 (en) | Improved cancer treatment with temozolomide | |
| PL371741A1 (pl) | Leczenie skojarzone ostrego zawału mięśnia sercowego | |
| AU2001236529A1 (en) | Combination therapy for cancer | |
| IL159770A0 (en) | Calcium salts with cytotoxic activity | |
| WO2006124573A3 (en) | Treatment of cancer with 2-deoxyglucose | |
| BRPI0407301A (pt) | Uso de uma combinação, composição farmacêutica, kit, e, método para o tratamento de câncer em um animal de sangue quente tal como um ser humano |